Previous 10 | Next 10 |
C4 Therapeutics press release ( NASDAQ: CCCC ): FY GAAP EPS of -$2.62 misses by $0.13 . Revenue of $31.1M (-32.1% Y/Y) misses by $8.69M . For further details see: C4 Therapeutics GAAP EPS of -$2.62 misses by $0.13, revenue of $31.1M misses by $8.69M
Phase 1 Dose Escalation Data from the Ongoing Phase 1/2 Clinical Trials of CFT7455, an IKZF1/3 MonoDAC™ Degrader, and CFT8634, a BRD9 BiDAC™ Degrader, Expected in 2H 2023 Phase 1/2 Clinical Trial of CFT1946, a BRAF V600 BiDAC Degrader, Enrolling Patients; New CFT1946...
WATERTOWN, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, toda...
The shares of clinical-stage biotech C4 Therapeutics ( NASDAQ: CCCC ) lost ~8% on Friday after announcing the resignation of Adam Crystal, who functioned as the company’s Chief Medical Officer for nearly four years. In a regulatory filing on Thursday after the market close,...
WATERTOWN, Mass., Jan. 30, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, toda...
Phase 1/2 Trial of CFT7455, an IKZF1/3 MonoDAC™ Degrader, Continues to Progress with Phase 1 Dose Escalation Data Expected in 2H 2023; Enrollment Open for Arm Evaluating CFT7455 in Combination with Dexamethasone Phase 1/2 Trial of CFT8634, a BRD9 BiDAC™ Degrade...
WATERTOWN, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, toda...
C4 Therapeutics press release ( NASDAQ: CCCC ): Q3 GAAP EPS of -$0.65 beats by $0.02 . Revenue of $6.8M (-20.0% Y/Y) misses by $2.46M . Cash, cash equivalents and marketable securities as of September 30, 2022, were $366.0 million, compared to $451.5 million as...
The Phase 1/2 Clinical Trials of CFT7455, an IKZF1/3 MonoDAC™ Degrader , and CFT8634, a BRD9 BiDAC™ Degrader, Continue to Enroll Patients and Advance Through Dose Escalation IND Clearance Achieved for CFT1946, a BRAF-V600 BiDAC Degrader; On Track to Initiat...
C4 Therapeutics, Inc. ( NASDAQ: CCCC ) added ~7% pre-market Thursday after the clinical-stage biotech announced that the FDA issued a Study May Proceed Letter to start a Phase 1/2 trial for its oral solid tumor candidate CFT1946. CFT1946 is designed to target the BRAF-...
News, Short Squeeze, Breakout and More Instantly...
WATERTOWN, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that preliminary data from the monotherapy dose escalation portion of the ongoing...
WATERTOWN, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will participate in a fireside chat at the UBS Targeted Prote...
Cooper Brings Decades of Global Pharmaceutical and Biotechnology Leadership Experience Bruce Downey Remains a Member of the Board of Directors and Chair of the Organization, Leadership and Compensation Committee Transition Further Highlights Commitment to Strategically Transform t...